secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001837607-26-000025
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma gets second NYSE American delisting notice over $55M equity deficit
--------------------------------------------------------------------------------

- March 31, 2026 notice: not compliant with Section 1003(a)(ii) requiring ≥$4M stockholders' equity.
- Stockholders' deficit ~$55M as of Dec 31, 2025; losses in 3 of last 4 fiscal years.
- Prior non-compliance (Section 1003(a)(i)) from Feb 2025; NYSE American accepted compliance plan through Aug 3, 2026.
- Stock continues trading under AEON with '.BC' indicator; company remains on noncompliant issuers list.
- Failure to regain compliance by Aug 3, 2026 could lead to delisting; business operations unaffected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000025/0001837607-26-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000025/aeon-20260331x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-26-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer